SlideShare una empresa de Scribd logo
1 de 20
Effects of Clinical Characteristics and Treatments on Gender Difference in Outcomes after Acute Myocardial Infarction. A propensity score-matched analysis François Schiele, MD, PhD, Nicolas Meneveau, MD, PhD,  Marie France Seronde, MD, Vincent Descotes-Genon, MD,  Joanna Dutheil, MD, Romain Chopard, MD, Fiona Ecarnot,  and Jean-Pierre Bassand, MD. On behalf on the “Reseau de Cardiologie de Franche Comté” Department of Cardiology, University Hospital Jean Minjoz,  Besançon, France. Confli c t of  Interest  to  Declare  : Research Contracts and Consulting Servier, Sanofi, GSK, Astra-Zeneca, Takeda, Lilly
Women fare worse than men after acute MI  ,[object Object],Malacrida, ISIS-3, N Engl J Med 1998;338:8-14
[object Object],[object Object],Women fare worse than men after acute MI  Malacrida, N Engl J Med 1998;338:8-14  ,[object Object],Vaccarino, N Engl J Med 1999;341:217-25  ,[object Object]
[object Object],[object Object],[object Object],Berger, JAMA 2009;302:874-82  Women fare worse than men after acute MI
[object Object],[object Object],[object Object],[object Object],Gan, N Engl J Med 2000;343:8-15  Women fare worse than men after acute MI
[object Object],[object Object],[object Object],[object Object],To assess the e ffects of Clinical Characteristics  and Treatments on Gender Difference ,  using a Propensity Score-Matched Analysis. Aim of the Study Women fare worse than men after acute MI
Methods ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Baseline characteristics (1) Variables Women (%) Men (%) P Value Chi2/ t N 1119 (32) 2391 (68) STEMI  461 (41) 1117 (47) 0.0008 9.38 NSTEMI  658 (59) 1274 (53) <0.0001 9.38 Age  (SD) 74 (13) 64 (13)  <0.0001 18.9 Diabetes 301 (27) 495 (21) <0.0001 16.7 Hypertension 762 (68) 1143 (48) <0.0001 12.7 Hypercholesterolemia 451 (40) 1132 (47) <0.0001 15.9 Smoker 258 (23) 1583 (66) <0.0001 56.7 Previous MI 151 (13) 449 (19) <0.0001 15.2 Previous angioplasty 94 (8) 349 (15) <0.0001 26.5 Previous coronary surgery 37 (3) 105 (4) 0.12 2.33 Previous Stroke 79 (7) 121 (5) 0.002 5.6 Per. Vessel Disease 86 (8) 286 (12) <0.0001 14.8
Baseline characteristics (2) Variables Women (%) Men (%) P Value Chi2/ t N 1119 (32) 2391 (68) Time to admission STEMI   4 [2;15] 3 [2 ;9]  <0.0001 Admission heart rate 80 (20) 77 (20) <0.0001 4.0 Admission Systolic BP  134 (29) 130 (28) 0.79 0.09 Killip class >2 94 (8) 127 (5) <0.0001 12.3 Cardiogenic shock 48 (4) 94 (4) 0.61 0.25 GRACE risk score 147 [124 ;167] 132 [110 ;152] <0.0001 Admission Glucose 7 (4.4) 6.7 (3.5) 0.0035 2.99 BNP 480 [180;1202]  217 [83;544] <0.0001 Hs-CRP 8 [3;27] 6 [2;22]  <0.0001
In-hospital Treatments  Variables Women (%) Men (%) P Value Chi2/ t Angiography 805 (72) 2080 (87) <0.0001 130 No obstructive disease 112(14) 92(4) <0.001 83 PCI of infarct related artery 552(49) 1662(69) <0.0001 133 GPIIbIIIa inhibitors (NSTEMI) 271 (40) 682 (53)  <0.0001 25.9 Reperfusion (STEMI) 281/461 (61) 843/1117 (75) <0.001 30.5 Primary PCI (STEMI) 215/461 (47) 615/1117 (55) <0.0001 19.0 Thrombolysis (STEMI) 66/461 ( 14) 228/1117 (20) <0.009 8.0 Aspirin 1089 (97) 2360 (99) <0.0001 16.8 Clopidogrel 1075 (96) 2290 (96) <0.0001 25.0 Aspirin + Clopidogrel 1035 (92) 2290 (96) <0.0001 31.8 ACEI / ARB 667  (60) 2052 (86) <0.0001 23.9 Betablockers 791 (71) 1847 (77) <0.0001 17.5 Statins 982 (88) 2296 (96) <0.0001 75.3
Selection of the matched populations 3510 patients with Acute Myocardial Infarction  1578 (45%) STEMI, 1932 (55%) NSTEMI 1119 (32%) Women, 2391 (68%) Men Matching on propensity score 1  = 649 pairs  Comparison of treatments Comparison of mortality Comparison of mortality Propensity score 1 (being male) with baseline characteristics Propensity score 2 (being male) with baseline characteristics and treatments Matching on propensity score 2  = 584 pairs
Effect of matching on sex differences P values for the difference between men and women  Unmatched dataset 0.05
Effect of matching on sex differences P values for the difference between men and women  Unmatched dataset Matched #1 dataset  0.05
Effect of matching on sex differences P values for the difference between men and women  Unmatched dataset Matched #1 dataset  Matched #2 dataset 0.05
KM Cumulative mortality Unmatched n=3510  p=0.001 Unmatched n=3510  p=0.001 Matched #1 n=649 pairs p=0.23 Log-Rank test: p=0.95 Days 0  5  10  20  30 At risk 584  574  565  544  529 584  573  562  550  530  Women Men Unmatched n=3510  p=0.001 Matched #1 n=649 pairs p=0.23 Matched #2 n=584 pairs p=0.95
0.5  0.8  1  1.5  2  4  Aspirin unmatched   OR= 1.35 [1.06; 1.80] Matched #1   OR= 1.10 [0.46; 2.62] Clopidogrel unmatched   OR= 1.65 [1.38; 2.01] Matched #1   OR= 1.04 [0.58; 1.84] Aspirin and Clopidogel unmatched   OR= 1.67 [1.40; 2.01] Matched #1   OR= 1.10 [0.46; 1.63] ACEI or ARB unmatched   OR= 1.42 [1.24; 1.65] Matched #1   OR= 1.29 [0.97; 1.70] Beta blocker unmatched   OR= 1.31 [1.15; 1.49] Matched #1   OR= 1.02 [0.64; 1.29] GPIIbIIIa (NSTEMI) unmatched   OR= 1.66 [1.43; 1.96] Matched #1   OR= 1.40 [0.94; 1.56] Coronary Angiography unmatched   OR= 2.82 [2.40; 3.41] Matched #1   OR= 1.57 [1.10; 2.18] Reperfusion /PPCI unmatched   OR= 1.56 [1.29; 1.89] Matched #1   OR= 1.24 [1.12; 1.71] Reperfusion /FL unmatched   OR= 1.82 [1.24; 2.12] Matched #1   OR= 1.72 [1.08; 2.73] In-Hospital mortality unmatched   OR= 0.50 [0.37; 0.62] Matched #1   OR= 0.52 [0.32; 0.83] Matched #2   OR= 0.75 [0.45; 1.23] 30 day mortality unmatched   OR= 0.53 [0.42; 0.57] Matched #1   OR= 0.70 [0.46; 1.01] Matched #2   OR= 0.89 [0.57; 1.36] Odds ratios for men versus women
Interaction between  Gender and type of MI Mort ality more than  twice as high in women than in men in STEMI, but no difference in NSTEMI patients; significant interaction No higher mortality and no interaction after adjustment for characteristics No higher mortality and no interaction after adjustment for characteristics and treatments Sub-groups (1) P=0.009 P=0.009 P=0.36 P=0.009 P=0.36 P=0.13
Interaction between Gender and Age: difference according to mean age Unadjusted cohort Sex-age interaction P=0.002 Matched #2 No sex-age interaction P=0.16 Matched #1 Sex-age interaction P=0.005 Sub-groups (2)
Discussion ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Vaccarino, New Engl J Med 1999  Austin, Use of PS.., Stat Med 2005  Berger, JAMA 2009;302:874-82  Blomkalns, CRUSADE, JACC 2005;45:832-7  Rosengren Eur Heart J 2001; 22: 314–322, Milcent Circulation. 2007;115:833-839
Conclusions ,[object Object],[object Object],[object Object]

Más contenido relacionado

La actualidad más candente

Macro complications 2018
Macro complications 2018Macro complications 2018
Macro complications 2018 Mohamed BADR
 
DRUG PROFILE IN MYOCARDIAL INFARCTION WITH MONITORING OF POSTLYSIS COMPLICATI...
DRUG PROFILE IN MYOCARDIAL INFARCTION WITH MONITORING OF POSTLYSIS COMPLICATI...DRUG PROFILE IN MYOCARDIAL INFARCTION WITH MONITORING OF POSTLYSIS COMPLICATI...
DRUG PROFILE IN MYOCARDIAL INFARCTION WITH MONITORING OF POSTLYSIS COMPLICATI...Sameer Shete
 
F. Saad - Highlights of Day 2 breakout sessions (Oncology room)
F. Saad - Highlights of Day 2 breakout sessions (Oncology room)F. Saad - Highlights of Day 2 breakout sessions (Oncology room)
F. Saad - Highlights of Day 2 breakout sessions (Oncology room)European School of Oncology
 
Diabetes mellitus and erectile dysfunction by Dr. Mohand Yaghi PgDip (urol) C...
Diabetes mellitus and erectile dysfunction by Dr. Mohand Yaghi PgDip (urol) C...Diabetes mellitus and erectile dysfunction by Dr. Mohand Yaghi PgDip (urol) C...
Diabetes mellitus and erectile dysfunction by Dr. Mohand Yaghi PgDip (urol) C...Mohand Yaghi
 
12 ème journée-Actualités sur la metformine
12 ème journée-Actualités sur la metformine12 ème journée-Actualités sur la metformine
12 ème journée-Actualités sur la metformineall-in-web
 
Kiem soat duong huyet tren tien dtd
Kiem soat duong huyet tren tien dtdKiem soat duong huyet tren tien dtd
Kiem soat duong huyet tren tien dtdkhacleson
 
Goal attainments and their discrepancies for low density lipoprotein choleste...
Goal attainments and their discrepancies for low density lipoprotein choleste...Goal attainments and their discrepancies for low density lipoprotein choleste...
Goal attainments and their discrepancies for low density lipoprotein choleste...Paul Schoenhagen
 
Lipid lowering trials ppt
Lipid lowering trials pptLipid lowering trials ppt
Lipid lowering trials pptNavin Agrawal
 
Esc np leader oral abs 86477 v13.0 2017 08-25
Esc np leader oral abs 86477 v13.0 2017 08-25Esc np leader oral abs 86477 v13.0 2017 08-25
Esc np leader oral abs 86477 v13.0 2017 08-25SoM
 
Alirocumab effect on new-onset or worsening diabetes, blood glucose, and HbA1c.
Alirocumab effect on new-onset or worsening diabetes, blood glucose, and HbA1c.Alirocumab effect on new-onset or worsening diabetes, blood glucose, and HbA1c.
Alirocumab effect on new-onset or worsening diabetes, blood glucose, and HbA1c.Marilyn Mann
 
aspirin effect on urinary thromboxane
aspirin effect on urinary thromboxaneaspirin effect on urinary thromboxane
aspirin effect on urinary thromboxaneguestfb7a
 

La actualidad más candente (19)

Strive Teleconf Presentation Apr11 2007
Strive Teleconf Presentation Apr11 2007Strive Teleconf Presentation Apr11 2007
Strive Teleconf Presentation Apr11 2007
 
Improve it slides
Improve it slidesImprove it slides
Improve it slides
 
Improve it
Improve itImprove it
Improve it
 
Bhnt
BhntBhnt
Bhnt
 
Erectile Dysfunction
Erectile DysfunctionErectile Dysfunction
Erectile Dysfunction
 
AHA: EMPHASIS-HF Trial
AHA: EMPHASIS-HF TrialAHA: EMPHASIS-HF Trial
AHA: EMPHASIS-HF Trial
 
Macro complications 2018
Macro complications 2018Macro complications 2018
Macro complications 2018
 
DRUG PROFILE IN MYOCARDIAL INFARCTION WITH MONITORING OF POSTLYSIS COMPLICATI...
DRUG PROFILE IN MYOCARDIAL INFARCTION WITH MONITORING OF POSTLYSIS COMPLICATI...DRUG PROFILE IN MYOCARDIAL INFARCTION WITH MONITORING OF POSTLYSIS COMPLICATI...
DRUG PROFILE IN MYOCARDIAL INFARCTION WITH MONITORING OF POSTLYSIS COMPLICATI...
 
F. Saad - Highlights of Day 2 breakout sessions (Oncology room)
F. Saad - Highlights of Day 2 breakout sessions (Oncology room)F. Saad - Highlights of Day 2 breakout sessions (Oncology room)
F. Saad - Highlights of Day 2 breakout sessions (Oncology room)
 
Diabetes mellitus and erectile dysfunction by Dr. Mohand Yaghi PgDip (urol) C...
Diabetes mellitus and erectile dysfunction by Dr. Mohand Yaghi PgDip (urol) C...Diabetes mellitus and erectile dysfunction by Dr. Mohand Yaghi PgDip (urol) C...
Diabetes mellitus and erectile dysfunction by Dr. Mohand Yaghi PgDip (urol) C...
 
2659.full
2659.full2659.full
2659.full
 
12 ème journée-Actualités sur la metformine
12 ème journée-Actualités sur la metformine12 ème journée-Actualités sur la metformine
12 ème journée-Actualités sur la metformine
 
Kiem soat duong huyet tren tien dtd
Kiem soat duong huyet tren tien dtdKiem soat duong huyet tren tien dtd
Kiem soat duong huyet tren tien dtd
 
Goal attainments and their discrepancies for low density lipoprotein choleste...
Goal attainments and their discrepancies for low density lipoprotein choleste...Goal attainments and their discrepancies for low density lipoprotein choleste...
Goal attainments and their discrepancies for low density lipoprotein choleste...
 
Lipid lowering trials ppt
Lipid lowering trials pptLipid lowering trials ppt
Lipid lowering trials ppt
 
Esc np leader oral abs 86477 v13.0 2017 08-25
Esc np leader oral abs 86477 v13.0 2017 08-25Esc np leader oral abs 86477 v13.0 2017 08-25
Esc np leader oral abs 86477 v13.0 2017 08-25
 
Alirocumab effect on new-onset or worsening diabetes, blood glucose, and HbA1c.
Alirocumab effect on new-onset or worsening diabetes, blood glucose, and HbA1c.Alirocumab effect on new-onset or worsening diabetes, blood glucose, and HbA1c.
Alirocumab effect on new-onset or worsening diabetes, blood glucose, and HbA1c.
 
aspirin effect on urinary thromboxane
aspirin effect on urinary thromboxaneaspirin effect on urinary thromboxane
aspirin effect on urinary thromboxane
 
Terapeuticas hormonais ...sesimbra
Terapeuticas hormonais ...sesimbraTerapeuticas hormonais ...sesimbra
Terapeuticas hormonais ...sesimbra
 

Similar a Gen Diff

NY Prostate Cancer Conference - F. Saad - Session 7: Predicting toxicity afte...
NY Prostate Cancer Conference - F. Saad - Session 7: Predicting toxicity afte...NY Prostate Cancer Conference - F. Saad - Session 7: Predicting toxicity afte...
NY Prostate Cancer Conference - F. Saad - Session 7: Predicting toxicity afte...European School of Oncology
 
ECCLU 2011 - B. Tombal - Side-effects of anti-androgen therapy
ECCLU 2011 - B. Tombal - Side-effects of anti-androgen therapyECCLU 2011 - B. Tombal - Side-effects of anti-androgen therapy
ECCLU 2011 - B. Tombal - Side-effects of anti-androgen therapyEuropean School of Oncology
 
Testosterone e cancro alla prostata
Testosterone e cancro alla prostataTestosterone e cancro alla prostata
Testosterone e cancro alla prostataAdmin Esanum IT
 
SYMCARD - Antiplatelet in ACS.pptx
SYMCARD - Antiplatelet in ACS.pptxSYMCARD - Antiplatelet in ACS.pptx
SYMCARD - Antiplatelet in ACS.pptxyansalvianto
 
Integrating icosapent ethyl in clinical practice: which patients will benefits?
Integrating icosapent ethyl in clinical practice: which patients will benefits?Integrating icosapent ethyl in clinical practice: which patients will benefits?
Integrating icosapent ethyl in clinical practice: which patients will benefits?Sociedad Española de Cardiología
 
Il rischio tromboembolico nelle patologie arteriose e venose della donna 3
Il rischio tromboembolico nelle patologie arteriose e venose della donna 3Il rischio tromboembolico nelle patologie arteriose e venose della donna 3
Il rischio tromboembolico nelle patologie arteriose e venose della donna 3Plinio Fabiani
 
Differences in clinical characteristics and its effect for outcomes
Differences in clinical characteristics and its effect for outcomesDifferences in clinical characteristics and its effect for outcomes
Differences in clinical characteristics and its effect for outcomesdrucsamal
 
Holly Thacker, Update on: Menopause, Hormone Therapy, Sex, Politics, and the ...
Holly Thacker, Update on: Menopause, Hormone Therapy, Sex, Politics, and the ...Holly Thacker, Update on: Menopause, Hormone Therapy, Sex, Politics, and the ...
Holly Thacker, Update on: Menopause, Hormone Therapy, Sex, Politics, and the ...Cleveland HeartLab, Inc.
 
Dyslipidemia -Assessment and management based on evidence
Dyslipidemia -Assessment and management based on evidence  Dyslipidemia -Assessment and management based on evidence
Dyslipidemia -Assessment and management based on evidence SYEDRAZA56411
 
Managing CV risk in Inflammatory Arthritis (Focusing on Gout)
Managing CV risk in Inflammatory Arthritis (Focusing on Gout)Managing CV risk in Inflammatory Arthritis (Focusing on Gout)
Managing CV risk in Inflammatory Arthritis (Focusing on Gout)Sidney Erwin Manahan
 
ADA20-Presentation-Slides-REDUCE-IT-DIABETES.pdf
ADA20-Presentation-Slides-REDUCE-IT-DIABETES.pdfADA20-Presentation-Slides-REDUCE-IT-DIABETES.pdf
ADA20-Presentation-Slides-REDUCE-IT-DIABETES.pdfMaiKhairy4
 
After Starting Therapy
After Starting TherapyAfter Starting Therapy
After Starting Therapydemiss
 

Similar a Gen Diff (20)

Gen diff
Gen diffGen diff
Gen diff
 
Strive Teleconf Presentation March22 2006
Strive Teleconf Presentation March22 2006Strive Teleconf Presentation March22 2006
Strive Teleconf Presentation March22 2006
 
Epidemiology: Sex/Gender and Health
Epidemiology: Sex/Gender and HealthEpidemiology: Sex/Gender and Health
Epidemiology: Sex/Gender and Health
 
NY Prostate Cancer Conference - F. Saad - Session 7: Predicting toxicity afte...
NY Prostate Cancer Conference - F. Saad - Session 7: Predicting toxicity afte...NY Prostate Cancer Conference - F. Saad - Session 7: Predicting toxicity afte...
NY Prostate Cancer Conference - F. Saad - Session 7: Predicting toxicity afte...
 
ECCLU 2011 - B. Tombal - Side-effects of anti-androgen therapy
ECCLU 2011 - B. Tombal - Side-effects of anti-androgen therapyECCLU 2011 - B. Tombal - Side-effects of anti-androgen therapy
ECCLU 2011 - B. Tombal - Side-effects of anti-androgen therapy
 
Testosterone e cancro alla prostata
Testosterone e cancro alla prostataTestosterone e cancro alla prostata
Testosterone e cancro alla prostata
 
SYMCARD - Antiplatelet in ACS.pptx
SYMCARD - Antiplatelet in ACS.pptxSYMCARD - Antiplatelet in ACS.pptx
SYMCARD - Antiplatelet in ACS.pptx
 
Integrating icosapent ethyl in clinical practice: which patients will benefits?
Integrating icosapent ethyl in clinical practice: which patients will benefits?Integrating icosapent ethyl in clinical practice: which patients will benefits?
Integrating icosapent ethyl in clinical practice: which patients will benefits?
 
Il rischio tromboembolico nelle patologie arteriose e venose della donna 3
Il rischio tromboembolico nelle patologie arteriose e venose della donna 3Il rischio tromboembolico nelle patologie arteriose e venose della donna 3
Il rischio tromboembolico nelle patologie arteriose e venose della donna 3
 
Differences in clinical characteristics and its effect for outcomes
Differences in clinical characteristics and its effect for outcomesDifferences in clinical characteristics and its effect for outcomes
Differences in clinical characteristics and its effect for outcomes
 
Holly Thacker, Update on: Menopause, Hormone Therapy, Sex, Politics, and the ...
Holly Thacker, Update on: Menopause, Hormone Therapy, Sex, Politics, and the ...Holly Thacker, Update on: Menopause, Hormone Therapy, Sex, Politics, and the ...
Holly Thacker, Update on: Menopause, Hormone Therapy, Sex, Politics, and the ...
 
Dyslipidemia -Assessment and management based on evidence
Dyslipidemia -Assessment and management based on evidence  Dyslipidemia -Assessment and management based on evidence
Dyslipidemia -Assessment and management based on evidence
 
Managing CV risk in Inflammatory Arthritis (Focusing on Gout)
Managing CV risk in Inflammatory Arthritis (Focusing on Gout)Managing CV risk in Inflammatory Arthritis (Focusing on Gout)
Managing CV risk in Inflammatory Arthritis (Focusing on Gout)
 
Noac workshop radionica
Noac workshop radionicaNoac workshop radionica
Noac workshop radionica
 
Race and Variations in Operative Treatment 10.22.09
Race and Variations in Operative Treatment 10.22.09Race and Variations in Operative Treatment 10.22.09
Race and Variations in Operative Treatment 10.22.09
 
Statin trials
Statin trials Statin trials
Statin trials
 
ADA20-Presentation-Slides-REDUCE-IT-DIABETES.pdf
ADA20-Presentation-Slides-REDUCE-IT-DIABETES.pdfADA20-Presentation-Slides-REDUCE-IT-DIABETES.pdf
ADA20-Presentation-Slides-REDUCE-IT-DIABETES.pdf
 
Wivon
WivonWivon
Wivon
 
Htn1
Htn1Htn1
Htn1
 
After Starting Therapy
After Starting TherapyAfter Starting Therapy
After Starting Therapy
 

Más de TriMed Media Group

HCLF 2013: Evidence at the Center of Care
HCLF 2013: Evidence at the Center of CareHCLF 2013: Evidence at the Center of Care
HCLF 2013: Evidence at the Center of CareTriMed Media Group
 
Forecast of Statin Market to 2018
Forecast of Statin Market to 2018Forecast of Statin Market to 2018
Forecast of Statin Market to 2018TriMed Media Group
 
PCPs speak out on rad reporting
PCPs speak out on rad reportingPCPs speak out on rad reporting
PCPs speak out on rad reportingTriMed Media Group
 
Step up to bat and practice dictating complex cases a residents guide to effe...
Step up to bat and practice dictating complex cases a residents guide to effe...Step up to bat and practice dictating complex cases a residents guide to effe...
Step up to bat and practice dictating complex cases a residents guide to effe...TriMed Media Group
 
Radiology Workflow: Recognizing Clinical & Financial Benefits of Implementing...
Radiology Workflow: Recognizing Clinical & Financial Benefits of Implementing...Radiology Workflow: Recognizing Clinical & Financial Benefits of Implementing...
Radiology Workflow: Recognizing Clinical & Financial Benefits of Implementing...TriMed Media Group
 
Inside a Private HIE: Clinical, Economic and Operational Successes at The Was...
Inside a Private HIE: Clinical, Economic and Operational Successes at The Was...Inside a Private HIE: Clinical, Economic and Operational Successes at The Was...
Inside a Private HIE: Clinical, Economic and Operational Successes at The Was...TriMed Media Group
 
How Healthcare Reform Is Affecting Radiology, Pam Kassing
How Healthcare Reform Is Affecting Radiology, Pam KassingHow Healthcare Reform Is Affecting Radiology, Pam Kassing
How Healthcare Reform Is Affecting Radiology, Pam KassingTriMed Media Group
 
Meaningful Use: Impact on Radiology, Arun Krishnaraj
Meaningful Use: Impact on Radiology, Arun KrishnarajMeaningful Use: Impact on Radiology, Arun Krishnaraj
Meaningful Use: Impact on Radiology, Arun KrishnarajTriMed Media Group
 
CMIO Summit 2011 | Reid Coleman
CMIO Summit 2011 | Reid ColemanCMIO Summit 2011 | Reid Coleman
CMIO Summit 2011 | Reid ColemanTriMed Media Group
 
2011 CMIO Summit | Justin Graham
2011 CMIO Summit | Justin Graham2011 CMIO Summit | Justin Graham
2011 CMIO Summit | Justin GrahamTriMed Media Group
 
2011 CMIO Summit | David Cochran
2011 CMIO Summit | David Cochran2011 CMIO Summit | David Cochran
2011 CMIO Summit | David CochranTriMed Media Group
 
2011 CMIO Summit | Brian McDonough
2011 CMIO Summit | Brian McDonough2011 CMIO Summit | Brian McDonough
2011 CMIO Summit | Brian McDonoughTriMed Media Group
 
2011 CMIO Summit | Abha Agrawal
2011 CMIO Summit | Abha Agrawal2011 CMIO Summit | Abha Agrawal
2011 CMIO Summit | Abha AgrawalTriMed Media Group
 

Más de TriMed Media Group (20)

2013 AMDIS Fall Symposium
2013 AMDIS Fall Symposium2013 AMDIS Fall Symposium
2013 AMDIS Fall Symposium
 
HCLF 2013: Evidence at the Center of Care
HCLF 2013: Evidence at the Center of CareHCLF 2013: Evidence at the Center of Care
HCLF 2013: Evidence at the Center of Care
 
2012 CMIO Leadership Forum
2012 CMIO Leadership Forum2012 CMIO Leadership Forum
2012 CMIO Leadership Forum
 
UPenn Oregon Telestroke
UPenn Oregon Telestroke UPenn Oregon Telestroke
UPenn Oregon Telestroke
 
Forecast of Statin Market to 2018
Forecast of Statin Market to 2018Forecast of Statin Market to 2018
Forecast of Statin Market to 2018
 
PCPs speak out on rad reporting
PCPs speak out on rad reportingPCPs speak out on rad reporting
PCPs speak out on rad reporting
 
Step up to bat and practice dictating complex cases a residents guide to effe...
Step up to bat and practice dictating complex cases a residents guide to effe...Step up to bat and practice dictating complex cases a residents guide to effe...
Step up to bat and practice dictating complex cases a residents guide to effe...
 
Radiology Workflow: Recognizing Clinical & Financial Benefits of Implementing...
Radiology Workflow: Recognizing Clinical & Financial Benefits of Implementing...Radiology Workflow: Recognizing Clinical & Financial Benefits of Implementing...
Radiology Workflow: Recognizing Clinical & Financial Benefits of Implementing...
 
RSNA 2012 - Photolog
RSNA 2012 - PhotologRSNA 2012 - Photolog
RSNA 2012 - Photolog
 
201209 cit-w&inicu
201209 cit-w&inicu201209 cit-w&inicu
201209 cit-w&inicu
 
Inside a Private HIE: Clinical, Economic and Operational Successes at The Was...
Inside a Private HIE: Clinical, Economic and Operational Successes at The Was...Inside a Private HIE: Clinical, Economic and Operational Successes at The Was...
Inside a Private HIE: Clinical, Economic and Operational Successes at The Was...
 
How Healthcare Reform Is Affecting Radiology, Pam Kassing
How Healthcare Reform Is Affecting Radiology, Pam KassingHow Healthcare Reform Is Affecting Radiology, Pam Kassing
How Healthcare Reform Is Affecting Radiology, Pam Kassing
 
Meaningful Use: Impact on Radiology, Arun Krishnaraj
Meaningful Use: Impact on Radiology, Arun KrishnarajMeaningful Use: Impact on Radiology, Arun Krishnaraj
Meaningful Use: Impact on Radiology, Arun Krishnaraj
 
CMIO Summit 2011 | Reid Coleman
CMIO Summit 2011 | Reid ColemanCMIO Summit 2011 | Reid Coleman
CMIO Summit 2011 | Reid Coleman
 
2011 CMIO Summit | Justin Graham
2011 CMIO Summit | Justin Graham2011 CMIO Summit | Justin Graham
2011 CMIO Summit | Justin Graham
 
2011 CMIO Summit | Don Levick
2011 CMIO Summit | Don Levick2011 CMIO Summit | Don Levick
2011 CMIO Summit | Don Levick
 
2011 CMIO Summit | David Cochran
2011 CMIO Summit | David Cochran2011 CMIO Summit | David Cochran
2011 CMIO Summit | David Cochran
 
2011 CMIO Summit | Brian McDonough
2011 CMIO Summit | Brian McDonough2011 CMIO Summit | Brian McDonough
2011 CMIO Summit | Brian McDonough
 
2011 CMIO Summit | Ben Stein
2011 CMIO Summit | Ben Stein2011 CMIO Summit | Ben Stein
2011 CMIO Summit | Ben Stein
 
2011 CMIO Summit | Abha Agrawal
2011 CMIO Summit | Abha Agrawal2011 CMIO Summit | Abha Agrawal
2011 CMIO Summit | Abha Agrawal
 

Último

The 7 Things I Know About Cyber Security After 25 Years | April 2024
The 7 Things I Know About Cyber Security After 25 Years | April 2024The 7 Things I Know About Cyber Security After 25 Years | April 2024
The 7 Things I Know About Cyber Security After 25 Years | April 2024Rafal Los
 
[2024]Digital Global Overview Report 2024 Meltwater.pdf
[2024]Digital Global Overview Report 2024 Meltwater.pdf[2024]Digital Global Overview Report 2024 Meltwater.pdf
[2024]Digital Global Overview Report 2024 Meltwater.pdfhans926745
 
08448380779 Call Girls In Greater Kailash - I Women Seeking Men
08448380779 Call Girls In Greater Kailash - I Women Seeking Men08448380779 Call Girls In Greater Kailash - I Women Seeking Men
08448380779 Call Girls In Greater Kailash - I Women Seeking MenDelhi Call girls
 
Install Stable Diffusion in windows machine
Install Stable Diffusion in windows machineInstall Stable Diffusion in windows machine
Install Stable Diffusion in windows machinePadma Pradeep
 
WhatsApp 9892124323 ✓Call Girls In Kalyan ( Mumbai ) secure service
WhatsApp 9892124323 ✓Call Girls In Kalyan ( Mumbai ) secure serviceWhatsApp 9892124323 ✓Call Girls In Kalyan ( Mumbai ) secure service
WhatsApp 9892124323 ✓Call Girls In Kalyan ( Mumbai ) secure servicePooja Nehwal
 
SQL Database Design For Developers at php[tek] 2024
SQL Database Design For Developers at php[tek] 2024SQL Database Design For Developers at php[tek] 2024
SQL Database Design For Developers at php[tek] 2024Scott Keck-Warren
 
Understanding the Laravel MVC Architecture
Understanding the Laravel MVC ArchitectureUnderstanding the Laravel MVC Architecture
Understanding the Laravel MVC ArchitecturePixlogix Infotech
 
#StandardsGoals for 2024: What’s new for BISAC - Tech Forum 2024
#StandardsGoals for 2024: What’s new for BISAC - Tech Forum 2024#StandardsGoals for 2024: What’s new for BISAC - Tech Forum 2024
#StandardsGoals for 2024: What’s new for BISAC - Tech Forum 2024BookNet Canada
 
Pigging Solutions in Pet Food Manufacturing
Pigging Solutions in Pet Food ManufacturingPigging Solutions in Pet Food Manufacturing
Pigging Solutions in Pet Food ManufacturingPigging Solutions
 
04-2024-HHUG-Sales-and-Marketing-Alignment.pptx
04-2024-HHUG-Sales-and-Marketing-Alignment.pptx04-2024-HHUG-Sales-and-Marketing-Alignment.pptx
04-2024-HHUG-Sales-and-Marketing-Alignment.pptxHampshireHUG
 
Automating Business Process via MuleSoft Composer | Bangalore MuleSoft Meetup...
Automating Business Process via MuleSoft Composer | Bangalore MuleSoft Meetup...Automating Business Process via MuleSoft Composer | Bangalore MuleSoft Meetup...
Automating Business Process via MuleSoft Composer | Bangalore MuleSoft Meetup...shyamraj55
 
SIEMENS: RAPUNZEL – A Tale About Knowledge Graph
SIEMENS: RAPUNZEL – A Tale About Knowledge GraphSIEMENS: RAPUNZEL – A Tale About Knowledge Graph
SIEMENS: RAPUNZEL – A Tale About Knowledge GraphNeo4j
 
From Event to Action: Accelerate Your Decision Making with Real-Time Automation
From Event to Action: Accelerate Your Decision Making with Real-Time AutomationFrom Event to Action: Accelerate Your Decision Making with Real-Time Automation
From Event to Action: Accelerate Your Decision Making with Real-Time AutomationSafe Software
 
Integration and Automation in Practice: CI/CD in Mule Integration and Automat...
Integration and Automation in Practice: CI/CD in Mule Integration and Automat...Integration and Automation in Practice: CI/CD in Mule Integration and Automat...
Integration and Automation in Practice: CI/CD in Mule Integration and Automat...Patryk Bandurski
 
AI as an Interface for Commercial Buildings
AI as an Interface for Commercial BuildingsAI as an Interface for Commercial Buildings
AI as an Interface for Commercial BuildingsMemoori
 
Azure Monitor & Application Insight to monitor Infrastructure & Application
Azure Monitor & Application Insight to monitor Infrastructure & ApplicationAzure Monitor & Application Insight to monitor Infrastructure & Application
Azure Monitor & Application Insight to monitor Infrastructure & ApplicationAndikSusilo4
 
Enhancing Worker Digital Experience: A Hands-on Workshop for Partners
Enhancing Worker Digital Experience: A Hands-on Workshop for PartnersEnhancing Worker Digital Experience: A Hands-on Workshop for Partners
Enhancing Worker Digital Experience: A Hands-on Workshop for PartnersThousandEyes
 
Scaling API-first – The story of a global engineering organization
Scaling API-first – The story of a global engineering organizationScaling API-first – The story of a global engineering organization
Scaling API-first – The story of a global engineering organizationRadu Cotescu
 
08448380779 Call Girls In Civil Lines Women Seeking Men
08448380779 Call Girls In Civil Lines Women Seeking Men08448380779 Call Girls In Civil Lines Women Seeking Men
08448380779 Call Girls In Civil Lines Women Seeking MenDelhi Call girls
 
Factors to Consider When Choosing Accounts Payable Services Providers.pptx
Factors to Consider When Choosing Accounts Payable Services Providers.pptxFactors to Consider When Choosing Accounts Payable Services Providers.pptx
Factors to Consider When Choosing Accounts Payable Services Providers.pptxKatpro Technologies
 

Último (20)

The 7 Things I Know About Cyber Security After 25 Years | April 2024
The 7 Things I Know About Cyber Security After 25 Years | April 2024The 7 Things I Know About Cyber Security After 25 Years | April 2024
The 7 Things I Know About Cyber Security After 25 Years | April 2024
 
[2024]Digital Global Overview Report 2024 Meltwater.pdf
[2024]Digital Global Overview Report 2024 Meltwater.pdf[2024]Digital Global Overview Report 2024 Meltwater.pdf
[2024]Digital Global Overview Report 2024 Meltwater.pdf
 
08448380779 Call Girls In Greater Kailash - I Women Seeking Men
08448380779 Call Girls In Greater Kailash - I Women Seeking Men08448380779 Call Girls In Greater Kailash - I Women Seeking Men
08448380779 Call Girls In Greater Kailash - I Women Seeking Men
 
Install Stable Diffusion in windows machine
Install Stable Diffusion in windows machineInstall Stable Diffusion in windows machine
Install Stable Diffusion in windows machine
 
WhatsApp 9892124323 ✓Call Girls In Kalyan ( Mumbai ) secure service
WhatsApp 9892124323 ✓Call Girls In Kalyan ( Mumbai ) secure serviceWhatsApp 9892124323 ✓Call Girls In Kalyan ( Mumbai ) secure service
WhatsApp 9892124323 ✓Call Girls In Kalyan ( Mumbai ) secure service
 
SQL Database Design For Developers at php[tek] 2024
SQL Database Design For Developers at php[tek] 2024SQL Database Design For Developers at php[tek] 2024
SQL Database Design For Developers at php[tek] 2024
 
Understanding the Laravel MVC Architecture
Understanding the Laravel MVC ArchitectureUnderstanding the Laravel MVC Architecture
Understanding the Laravel MVC Architecture
 
#StandardsGoals for 2024: What’s new for BISAC - Tech Forum 2024
#StandardsGoals for 2024: What’s new for BISAC - Tech Forum 2024#StandardsGoals for 2024: What’s new for BISAC - Tech Forum 2024
#StandardsGoals for 2024: What’s new for BISAC - Tech Forum 2024
 
Pigging Solutions in Pet Food Manufacturing
Pigging Solutions in Pet Food ManufacturingPigging Solutions in Pet Food Manufacturing
Pigging Solutions in Pet Food Manufacturing
 
04-2024-HHUG-Sales-and-Marketing-Alignment.pptx
04-2024-HHUG-Sales-and-Marketing-Alignment.pptx04-2024-HHUG-Sales-and-Marketing-Alignment.pptx
04-2024-HHUG-Sales-and-Marketing-Alignment.pptx
 
Automating Business Process via MuleSoft Composer | Bangalore MuleSoft Meetup...
Automating Business Process via MuleSoft Composer | Bangalore MuleSoft Meetup...Automating Business Process via MuleSoft Composer | Bangalore MuleSoft Meetup...
Automating Business Process via MuleSoft Composer | Bangalore MuleSoft Meetup...
 
SIEMENS: RAPUNZEL – A Tale About Knowledge Graph
SIEMENS: RAPUNZEL – A Tale About Knowledge GraphSIEMENS: RAPUNZEL – A Tale About Knowledge Graph
SIEMENS: RAPUNZEL – A Tale About Knowledge Graph
 
From Event to Action: Accelerate Your Decision Making with Real-Time Automation
From Event to Action: Accelerate Your Decision Making with Real-Time AutomationFrom Event to Action: Accelerate Your Decision Making with Real-Time Automation
From Event to Action: Accelerate Your Decision Making with Real-Time Automation
 
Integration and Automation in Practice: CI/CD in Mule Integration and Automat...
Integration and Automation in Practice: CI/CD in Mule Integration and Automat...Integration and Automation in Practice: CI/CD in Mule Integration and Automat...
Integration and Automation in Practice: CI/CD in Mule Integration and Automat...
 
AI as an Interface for Commercial Buildings
AI as an Interface for Commercial BuildingsAI as an Interface for Commercial Buildings
AI as an Interface for Commercial Buildings
 
Azure Monitor & Application Insight to monitor Infrastructure & Application
Azure Monitor & Application Insight to monitor Infrastructure & ApplicationAzure Monitor & Application Insight to monitor Infrastructure & Application
Azure Monitor & Application Insight to monitor Infrastructure & Application
 
Enhancing Worker Digital Experience: A Hands-on Workshop for Partners
Enhancing Worker Digital Experience: A Hands-on Workshop for PartnersEnhancing Worker Digital Experience: A Hands-on Workshop for Partners
Enhancing Worker Digital Experience: A Hands-on Workshop for Partners
 
Scaling API-first – The story of a global engineering organization
Scaling API-first – The story of a global engineering organizationScaling API-first – The story of a global engineering organization
Scaling API-first – The story of a global engineering organization
 
08448380779 Call Girls In Civil Lines Women Seeking Men
08448380779 Call Girls In Civil Lines Women Seeking Men08448380779 Call Girls In Civil Lines Women Seeking Men
08448380779 Call Girls In Civil Lines Women Seeking Men
 
Factors to Consider When Choosing Accounts Payable Services Providers.pptx
Factors to Consider When Choosing Accounts Payable Services Providers.pptxFactors to Consider When Choosing Accounts Payable Services Providers.pptx
Factors to Consider When Choosing Accounts Payable Services Providers.pptx
 

Gen Diff

  • 1. Effects of Clinical Characteristics and Treatments on Gender Difference in Outcomes after Acute Myocardial Infarction. A propensity score-matched analysis François Schiele, MD, PhD, Nicolas Meneveau, MD, PhD, Marie France Seronde, MD, Vincent Descotes-Genon, MD, Joanna Dutheil, MD, Romain Chopard, MD, Fiona Ecarnot, and Jean-Pierre Bassand, MD. On behalf on the “Reseau de Cardiologie de Franche Comté” Department of Cardiology, University Hospital Jean Minjoz, Besançon, France. Confli c t of Interest to Declare : Research Contracts and Consulting Servier, Sanofi, GSK, Astra-Zeneca, Takeda, Lilly
  • 2.
  • 3.
  • 4.
  • 5.
  • 6.
  • 7.
  • 8. Baseline characteristics (1) Variables Women (%) Men (%) P Value Chi2/ t N 1119 (32) 2391 (68) STEMI  461 (41) 1117 (47) 0.0008 9.38 NSTEMI  658 (59) 1274 (53) <0.0001 9.38 Age (SD) 74 (13) 64 (13)  <0.0001 18.9 Diabetes 301 (27) 495 (21) <0.0001 16.7 Hypertension 762 (68) 1143 (48) <0.0001 12.7 Hypercholesterolemia 451 (40) 1132 (47) <0.0001 15.9 Smoker 258 (23) 1583 (66) <0.0001 56.7 Previous MI 151 (13) 449 (19) <0.0001 15.2 Previous angioplasty 94 (8) 349 (15) <0.0001 26.5 Previous coronary surgery 37 (3) 105 (4) 0.12 2.33 Previous Stroke 79 (7) 121 (5) 0.002 5.6 Per. Vessel Disease 86 (8) 286 (12) <0.0001 14.8
  • 9. Baseline characteristics (2) Variables Women (%) Men (%) P Value Chi2/ t N 1119 (32) 2391 (68) Time to admission STEMI  4 [2;15] 3 [2 ;9]  <0.0001 Admission heart rate 80 (20) 77 (20) <0.0001 4.0 Admission Systolic BP 134 (29) 130 (28) 0.79 0.09 Killip class >2 94 (8) 127 (5) <0.0001 12.3 Cardiogenic shock 48 (4) 94 (4) 0.61 0.25 GRACE risk score 147 [124 ;167] 132 [110 ;152] <0.0001 Admission Glucose 7 (4.4) 6.7 (3.5) 0.0035 2.99 BNP 480 [180;1202]  217 [83;544] <0.0001 Hs-CRP 8 [3;27] 6 [2;22]  <0.0001
  • 10. In-hospital Treatments Variables Women (%) Men (%) P Value Chi2/ t Angiography 805 (72) 2080 (87) <0.0001 130 No obstructive disease 112(14) 92(4) <0.001 83 PCI of infarct related artery 552(49) 1662(69) <0.0001 133 GPIIbIIIa inhibitors (NSTEMI) 271 (40) 682 (53)  <0.0001 25.9 Reperfusion (STEMI) 281/461 (61) 843/1117 (75) <0.001 30.5 Primary PCI (STEMI) 215/461 (47) 615/1117 (55) <0.0001 19.0 Thrombolysis (STEMI) 66/461 ( 14) 228/1117 (20) <0.009 8.0 Aspirin 1089 (97) 2360 (99) <0.0001 16.8 Clopidogrel 1075 (96) 2290 (96) <0.0001 25.0 Aspirin + Clopidogrel 1035 (92) 2290 (96) <0.0001 31.8 ACEI / ARB 667 (60) 2052 (86) <0.0001 23.9 Betablockers 791 (71) 1847 (77) <0.0001 17.5 Statins 982 (88) 2296 (96) <0.0001 75.3
  • 11. Selection of the matched populations 3510 patients with Acute Myocardial Infarction 1578 (45%) STEMI, 1932 (55%) NSTEMI 1119 (32%) Women, 2391 (68%) Men Matching on propensity score 1 = 649 pairs Comparison of treatments Comparison of mortality Comparison of mortality Propensity score 1 (being male) with baseline characteristics Propensity score 2 (being male) with baseline characteristics and treatments Matching on propensity score 2 = 584 pairs
  • 12. Effect of matching on sex differences P values for the difference between men and women Unmatched dataset 0.05
  • 13. Effect of matching on sex differences P values for the difference between men and women Unmatched dataset Matched #1 dataset 0.05
  • 14. Effect of matching on sex differences P values for the difference between men and women Unmatched dataset Matched #1 dataset Matched #2 dataset 0.05
  • 15. KM Cumulative mortality Unmatched n=3510 p=0.001 Unmatched n=3510 p=0.001 Matched #1 n=649 pairs p=0.23 Log-Rank test: p=0.95 Days 0 5 10 20 30 At risk 584 574 565 544 529 584 573 562 550 530 Women Men Unmatched n=3510 p=0.001 Matched #1 n=649 pairs p=0.23 Matched #2 n=584 pairs p=0.95
  • 16. 0.5 0.8 1 1.5 2 4 Aspirin unmatched OR= 1.35 [1.06; 1.80] Matched #1 OR= 1.10 [0.46; 2.62] Clopidogrel unmatched OR= 1.65 [1.38; 2.01] Matched #1 OR= 1.04 [0.58; 1.84] Aspirin and Clopidogel unmatched OR= 1.67 [1.40; 2.01] Matched #1 OR= 1.10 [0.46; 1.63] ACEI or ARB unmatched OR= 1.42 [1.24; 1.65] Matched #1 OR= 1.29 [0.97; 1.70] Beta blocker unmatched OR= 1.31 [1.15; 1.49] Matched #1 OR= 1.02 [0.64; 1.29] GPIIbIIIa (NSTEMI) unmatched OR= 1.66 [1.43; 1.96] Matched #1 OR= 1.40 [0.94; 1.56] Coronary Angiography unmatched OR= 2.82 [2.40; 3.41] Matched #1 OR= 1.57 [1.10; 2.18] Reperfusion /PPCI unmatched OR= 1.56 [1.29; 1.89] Matched #1 OR= 1.24 [1.12; 1.71] Reperfusion /FL unmatched OR= 1.82 [1.24; 2.12] Matched #1 OR= 1.72 [1.08; 2.73] In-Hospital mortality unmatched OR= 0.50 [0.37; 0.62] Matched #1 OR= 0.52 [0.32; 0.83] Matched #2 OR= 0.75 [0.45; 1.23] 30 day mortality unmatched OR= 0.53 [0.42; 0.57] Matched #1 OR= 0.70 [0.46; 1.01] Matched #2 OR= 0.89 [0.57; 1.36] Odds ratios for men versus women
  • 17. Interaction between Gender and type of MI Mort ality more than twice as high in women than in men in STEMI, but no difference in NSTEMI patients; significant interaction No higher mortality and no interaction after adjustment for characteristics No higher mortality and no interaction after adjustment for characteristics and treatments Sub-groups (1) P=0.009 P=0.009 P=0.36 P=0.009 P=0.36 P=0.13
  • 18. Interaction between Gender and Age: difference according to mean age Unadjusted cohort Sex-age interaction P=0.002 Matched #2 No sex-age interaction P=0.16 Matched #1 Sex-age interaction P=0.005 Sub-groups (2)
  • 19.
  • 20.

Notas del editor

  1. ISIS3 = il y a 20 ans (publié lancet 92)
  2. Malacrida= 20 ans; Vaccarino = 380000 patients de NRMI, exclu les transferts, &gt;90 ans, &lt;30 ans, admission depuis 1998
  3. Meta analyse depuis Gusto2b (93) jusqu’à Gusto4 (2001), 35128 pts
  4. Medicare, 139000 patients, pas de transferts, admis entre 94 et 95
  5. CRUSADE entre 2000 et 2002